4-(2-chloropyrido[3,2-d]pyrimidin-4-yl)morpholine | 53840-89-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 4-(2-chloropyrido[3,2-d]pyrimidin-4-yl)morpholine
• CAS: 53840-89-4
• 化学式: C₁₁H₁₁ClN₄O
• 分子量: 250.688
• InChiKey: OAHVKDKOTHFPMP-UHFFFAOYSA-N

物化性质

• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-chloropyrido[3,2-d]pyrimidin-4-yl)morpholine 在 tin(II) chloride dihdyrate 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 38.0h， 生成 2-(4-(1-(4-hydroxyphenyl)-3-phenylurea))-4-morpholinopyrido[3,2-d]pyrimidine
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual Inhibitors

  摘要：

  The design, synthesis, and screening of dual PI3K/mTOR inhibitors that gave nanomolar enzymatic and cellular activities on both targets with an acceptable kinase selectivity profile are described. A docking study was performed to understand the binding mode of the compounds and to explain the differences in biological activity. In addition, cellular effects of the best dual inhibitors were determined on six cancer cell lines and compared to those on a healthy diploid cell line for cellular cytotoxicity. Two compounds are highly potent on cancer cells in the submicromolar range without any toxicity on healthy cells. A more detailed analysis of the cellular effect of these PI3K/mTOR dual inhibitors demonstrated that they induce GI-phase cell cycle arrest in breast cancer cells and trigger apoptosis. These compounds show an interesting kinase profile as dual PI3K/mTOR tool compounds or as a chemical series for further optimization to progress into in vivo experiments.

  DOI：

  10.1021/jm401138v
• 作为产物：
  描述：

  3-氨基吡啶-2-羧酸 在 三乙胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 3.0h， 生成 4-(2-chloropyrido[3,2-d]pyrimidin-4-yl)morpholine
  参考文献：
  名称：

  [EN] PYRIDOPYRIMIDINES AND METHODS OF THEIR USE
  [FR] PYRIDOPYRIMIDINES ET LEURS MÉTHODES D'UTILISATION

  摘要：

  本文披露了在治疗神经系统疾病中有用的化合物。这些化合物可以单独或与其他药理活性剂结合使用，用于治疗或预防神经系统疾病。

  公开号：

  WO2021247859A1

文献信息

• Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors
  作者：Aisha A.K. Al-Ashmawy、Fatma A. Ragab、Khaled M. Elokely、Manal M. Anwar、Oscar Perez-Leal、Mario C. Rico、John Gordon、Eugeney Bichenkov、George Mateo、Emad M.M. Kassem、Gehan H. Hegazy、Magid Abou-Gharbia、Wayne Childers

  DOI：10.1016/j.bmcl.2017.05.044

  日期：2017.7

  PI3Kα/mTOR ATP-competitive inhibitors are considered as one of the promising molecularly targeted cancer therapeutics. Based on lead compound A from the literature, two similar series of 2-substituted-4-morpholino-pyrido[3,2-d]pyrimidine and pyrido[2,3-d]pyrimidine analogs were designed and synthesized as PI3Kα/mTOR dual inhibitors. Interestingly, most of the series gave excellent inhibition for both

  PI3Kα/ mTOR ATP竞争性抑制剂被认为是有前途的分子靶向癌症治疗剂之一。基于文献中的铅化合物A，设计并合成了两个相似的2-取代-4-吗啉代-吡啶并[3,2- d ]嘧啶和吡啶并[2,3- d ]嘧啶类似物系列，并将其合成为PI3Kα/ mTOR dual抑制剂。有趣的是，大多数系列均对两种酶均具有优异的抑制作用，IC 50值范围从一位到两位数nM。与许多PI3Kα/ mTOR双重抑制剂不同，我们的化合物显示出对PI3Kα的选择性。基于其强大的酶抑制活性，对PI3Kα的选择性以及在2D细胞培养活力测定中良好的治疗指数，化合物4h选择在3D培养中评估其针对MCF7乳腺癌细胞的IC 50以及与这两种酶的对接研究。
• PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20110207713A1

  公开（公告）日：2011-08-25

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I 化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制 PI3K 的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用 Formula I 化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病，或相关病理条件的方法。
• 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES
  申请人：Pomel Vincent

  公开号：US20110257170A1

  公开（公告）日：2011-10-20

  This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.

  本发明涉及化合物式（I）的Pi3k抑制剂，用于治疗自身免疫性疾病、炎症性疾病、多发性硬化和其他疾病，如癌症。
• [EN] 4 -MORPHOLINO-PYRIDO [3, 2 -D] PYRIMIDINES ACTIVE ON PI3K<br/>[FR] 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES
  申请人：MERCK SERONO SA

  公开号：WO2010037765A3

  公开（公告）日：2010-07-15
• The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase
  作者：Karine Malagu、Heather Duggan、Keith Menear、Marc Hummersone、Sylvie Gomez、Christine Bailey、Peter Edwards、Jan Drzewiecki、Frédéric Leroux、Mar Jimenez Quesada、Gesine Hermann、Stephanie Maine、Carrie-Anne Molyneaux、Armelle Le Gall、James Pullen、Ian Hickson、Lisa Smith、Sharon Maguire、Niall Martin、Graeme Smith、Martin Pass

  DOI：10.1016/j.bmcl.2009.08.038

  日期：2009.10

  We describe a novel series of potent inhibitors of the kinase activity of mTOR. The compounds display good selectivity relative to other PI3K-related kinase family members and, in cellular assays, inhibit both mTORC1 and mTORC2 complexes and exhibit good antiproliferative activity. (C) 2009 Elsevier Ltd. All rights reserved.